search
Back to results

Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy

Primary Purpose

Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Carbon Dioxide Fractional Laser
Questionnaire Administration
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anatomic Stage 0 Breast Cancer AJCC v8

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histological confirmation of adenocarcinoma of the breast stage 0-III
  • Evidence of hormone sensitivity with estrogen receptor (ER) and/or progesterone receptor (PR) positive >= 1% of primary tumor tissue
  • Currently or will be starting on aromatase inhibitor (letrozole, anastrozole, or exemestane)
  • Willingness to self-report vaginal itching, dryness, or dyspareunia
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
  • Obtained =< 28 days prior to registration: Hemoglobin >= 8.0 g/dL
  • Obtained =< 28 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3
  • Obtained =< 28 days prior to registration: Platelet count >= 75,000/mm^3
  • Obtained =< 28 days prior to registration: Total bilirubin =< 3.0 x upper limit of normal (ULN)
  • Obtained =< 28 days prior to registration: Aspartate transaminase (AST) =< 3 x ULN
  • Obtained =< 28 days prior to registration: Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =< 2 x ULN OR if patient is receiving anticoagulant therapy and PT/INR or partial thromboplastin time (PTT) is within therapeutic range of intended use of coagulants
  • Obtained =< 28 days prior to registration: Calculated creatinine clearance =< 3 x ULN
  • Recent negative Papanicolaou (PAP) smear within 1 year. In patients who do not have recent PAP smear, PAP smear should be obtained as per standard of care during the screening process prior to enrollment
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Provide written informed consent
  • Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)

Exclusion Criteria:

  • Previous use of CO2 fractional within 1 year
  • Receiving any form of hormone replacement therapy, including topical estrogens, testosterone, and dehydroepiandrosterone (DHEA) or selective estrogen receptor modulator (SERM), including tamoxifen and ospemifene
  • History of or current dysplastic nevi in the area that will be treated
  • Prolapse uterus > stage II according to the International Continence Society pelvic organ prolapse quantification (ICS-POP-Q) system
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of the treatment
  • Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy. NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Evidence of urinary tract infection (UTI) based on the urinalysis (UA) at the time of the screening. Patients with evidence of UTI can be enrolled after UTI is treated and repeated UA and/or urine culture shows no further evidence of ongoing infection
  • Evidence of injuries, bleeding, or evidence suggestive of dysplasia in the external vaginal area or vaginal canal

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Treatment (carbon dioxide fractional laser)

    Arm Description

    Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

    Outcomes

    Primary Outcome Measures

    Reduction in Vulvovaginal Symptom Questionnaire (VSQ) (symptoms, emotions, and life-impact)
    Descriptive statistics (mean, standard deviation [SD], median, interquartile range [IQR]) using frequency table and histogram will be used to summarize the reduction in the sum of VSQ total score first three scales of the VSQ (symptoms, emotions, and life-impact) at 3 months after treatment versus (vs.) baseline.

    Secondary Outcome Measures

    Reduction in VSQ score (symptoms, emotions, and life-impact)
    Will evaluate the sum of first three scales of the VSQ (symptoms, emotions, and life impact), VSQ total scale, and sub-scales. Descriptive statistics (mean, SD, median, IQR) and longitudinal plots (raw value, change, change in percentage) will be used to summarize the sum of VSQ total score first three scales of the VSQ (symptoms, emotions, and life-impact), VSQ total scale and subscales.
    Female Sexual Function Index (FSFI) score
    Descriptive statistics (mean, SD, median, IQR) and will be used to summarize FSFI total score and subscales before and after treatment.
    Urogenital Distress Inventory (UDI) 6 score
    Descriptive statistics (mean, SD, median, IQR) and will be used to summarize UDI-6 score before and after treatment.
    Vaginal health index score
    Descriptive statistics (frequency table) and histogram will be used to summarize vaginal health index score before and after treatment.
    Vaginal caliber
    Descriptive statistics (mean, SD, median, IQR) and will be used to summarize vaginal caliber before and after treatment.
    Discomfort and pain during carbon dioxide fractional (CO2RE) laser treatment using the visual analog scale
    Descriptive statistics (mean, SD, median, IQR) and will be used to summarize the visual analogue pain scale during treatment.
    Treatment satisfaction as measured by 5-point Likert scale
    Descriptive statistics (frequency table) and histogram will be used to summarize treatment satisfaction after CO2RE laser treatment using 5-point Likert scale during follow-up
    Adherence to aromatase inhibitor as measured by the Simplified Medication Adherence Questionnaire
    Descriptive statistics (frequency table) and histogram will be used to summarize the Simplified Medication Adherence Questionnaire during follow-up.
    Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
    The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine adverse event patterns.

    Full Information

    First Posted
    September 10, 2018
    Last Updated
    January 5, 2023
    Sponsor
    Mayo Clinic
    Collaborators
    National Cancer Institute (NCI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03666819
    Brief Title
    Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
    Official Title
    Phase II Trial of CO2RE Laser for Patients With Stage 0-III Hormone Receptor-Positive Breast Cancer on Aromatase Inhibitors With Vulvovaginal Atrophy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2018
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Manufacturer will not be supporting this study
    Study Start Date
    September 10, 2018 (Anticipated)
    Primary Completion Date
    September 10, 2021 (Anticipated)
    Study Completion Date
    September 10, 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Mayo Clinic
    Collaborators
    National Cancer Institute (NCI)

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This phase II trial studies how well carbon dioxide fractional (CO2RE) laser works in treating participants with stage 0-III hormone receptor-positive breast cancer with vulvovaginal atrophy associated with dryness, inflammation or thinning of the epithelial lining of the vulva and vagina. CO2RE laser is a device that delivers controlled CO2 energy to the vaginal tissue and may help treat vaginal symptoms such as itching, burning, painful sexual intercourse, thickened or thin skin of the vulva, and stinging.
    Detailed Description
    PRIMARY OBJECTIVES: I. To evaluate the reduction in Vulvovaginal Symptom Questionnaire (VSQ) score at 3-month follow up after CO2RE laser treatment. SECONDARY OBJECTIVES: I. To evaluate the reduction in VSQ score after CO2RE laser treatment 6-month follow-up and 12-month follow-up. II. To evaluate Female Sexual Function Index (FSFI) score before and after treatment with CO2RE laser. III. To evaluate Urogenital Distress Inventory (UDI) 6 score before and after treatment with CO2RE laser. IV. To evaluate vaginal health index score and vaginal caliber before and after treatment with CO2RE laser. V. To evaluate discomfort and pain during CO2RE laser treatment using the visual analog scale. VI. To evaluate treatment satisfaction after CO2RE laser treatment using 5-point Likert scale. VII. To evaluate adherence to aromatase inhibitor at 6 and 12 months after CO2RE laser treatment. EXPLORATORY OBJECTIVES: I. To assess the change in the vaginal cytology using vaginal maturation index at baseline and during follow-up. II. To assess serum estradiol level at baseline and after CO2RE laser treatment. OUTLINE: Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, participants are followed up at 3, 6, and 12 months.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Adenocarcinoma, Dyspareunia, Estrogen Receptor Positive, Progesterone Receptor Positive, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Vaginal Dryness, Vaginal Itching, Vulvovaginal Atrophy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Treatment (carbon dioxide fractional laser)
    Arm Type
    Experimental
    Arm Description
    Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
    Intervention Type
    Device
    Intervention Name(s)
    Carbon Dioxide Fractional Laser
    Other Intervention Name(s)
    CO2 Fractional Laser
    Intervention Description
    Undergo CO2RE laser therapy
    Intervention Type
    Other
    Intervention Name(s)
    Questionnaire Administration
    Intervention Description
    Ancillary studies
    Primary Outcome Measure Information:
    Title
    Reduction in Vulvovaginal Symptom Questionnaire (VSQ) (symptoms, emotions, and life-impact)
    Description
    Descriptive statistics (mean, standard deviation [SD], median, interquartile range [IQR]) using frequency table and histogram will be used to summarize the reduction in the sum of VSQ total score first three scales of the VSQ (symptoms, emotions, and life-impact) at 3 months after treatment versus (vs.) baseline.
    Time Frame
    Baseline up to 3 months
    Secondary Outcome Measure Information:
    Title
    Reduction in VSQ score (symptoms, emotions, and life-impact)
    Description
    Will evaluate the sum of first three scales of the VSQ (symptoms, emotions, and life impact), VSQ total scale, and sub-scales. Descriptive statistics (mean, SD, median, IQR) and longitudinal plots (raw value, change, change in percentage) will be used to summarize the sum of VSQ total score first three scales of the VSQ (symptoms, emotions, and life-impact), VSQ total scale and subscales.
    Time Frame
    Baseline up to 12 months
    Title
    Female Sexual Function Index (FSFI) score
    Description
    Descriptive statistics (mean, SD, median, IQR) and will be used to summarize FSFI total score and subscales before and after treatment.
    Time Frame
    Baseline up to 12 months
    Title
    Urogenital Distress Inventory (UDI) 6 score
    Description
    Descriptive statistics (mean, SD, median, IQR) and will be used to summarize UDI-6 score before and after treatment.
    Time Frame
    Baseline up to 12 months
    Title
    Vaginal health index score
    Description
    Descriptive statistics (frequency table) and histogram will be used to summarize vaginal health index score before and after treatment.
    Time Frame
    Baseline up to 12 months
    Title
    Vaginal caliber
    Description
    Descriptive statistics (mean, SD, median, IQR) and will be used to summarize vaginal caliber before and after treatment.
    Time Frame
    Baseline up to 12 months
    Title
    Discomfort and pain during carbon dioxide fractional (CO2RE) laser treatment using the visual analog scale
    Description
    Descriptive statistics (mean, SD, median, IQR) and will be used to summarize the visual analogue pain scale during treatment.
    Time Frame
    Up to 12 months
    Title
    Treatment satisfaction as measured by 5-point Likert scale
    Description
    Descriptive statistics (frequency table) and histogram will be used to summarize treatment satisfaction after CO2RE laser treatment using 5-point Likert scale during follow-up
    Time Frame
    Up to 12 months
    Title
    Adherence to aromatase inhibitor as measured by the Simplified Medication Adherence Questionnaire
    Description
    Descriptive statistics (frequency table) and histogram will be used to summarize the Simplified Medication Adherence Questionnaire during follow-up.
    Time Frame
    Up to 12 months
    Title
    Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
    Description
    The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine adverse event patterns.
    Time Frame
    Up to 12 months
    Other Pre-specified Outcome Measures:
    Title
    Change in vaginal cytology using vaginal maturation index
    Description
    Descriptive statistics (mean, SD, median, IQR) and longitudinal plots (raw value, change, change in percentage) will be used to summarize the change in the vaginal cytology using vaginal maturation index.
    Time Frame
    Baseline up to 12 months
    Title
    Assessment of serum estradiol levels
    Description
    Descriptive statistics (mean, SD, median, IQR) and longitudinal plots (raw value, change, change in percentage) will be used to summarize serum estradiol level at baseline and after CO2RE laser treatment and the change from baseline.
    Time Frame
    Baseline up to 12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Histological confirmation of adenocarcinoma of the breast stage 0-III Evidence of hormone sensitivity with estrogen receptor (ER) and/or progesterone receptor (PR) positive >= 1% of primary tumor tissue Currently or will be starting on aromatase inhibitor (letrozole, anastrozole, or exemestane) Willingness to self-report vaginal itching, dryness, or dyspareunia Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 Obtained =< 28 days prior to registration: Hemoglobin >= 8.0 g/dL Obtained =< 28 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3 Obtained =< 28 days prior to registration: Platelet count >= 75,000/mm^3 Obtained =< 28 days prior to registration: Total bilirubin =< 3.0 x upper limit of normal (ULN) Obtained =< 28 days prior to registration: Aspartate transaminase (AST) =< 3 x ULN Obtained =< 28 days prior to registration: Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =< 2 x ULN OR if patient is receiving anticoagulant therapy and PT/INR or partial thromboplastin time (PTT) is within therapeutic range of intended use of coagulants Obtained =< 28 days prior to registration: Calculated creatinine clearance =< 3 x ULN Recent negative Papanicolaou (PAP) smear within 1 year. In patients who do not have recent PAP smear, PAP smear should be obtained as per standard of care during the screening process prior to enrollment Ability to complete questionnaire(s) by themselves or with assistance Provide written informed consent Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study) Exclusion Criteria: Previous use of CO2 fractional within 1 year Receiving any form of hormone replacement therapy, including topical estrogens, testosterone, and dehydroepiandrosterone (DHEA) or selective estrogen receptor modulator (SERM), including tamoxifen and ospemifene History of or current dysplastic nevi in the area that will be treated Prolapse uterus > stage II according to the International Continence Society pelvic organ prolapse quantification (ICS-POP-Q) system Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of the treatment Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy. NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Evidence of urinary tract infection (UTI) based on the urinalysis (UA) at the time of the screening. Patients with evidence of UTI can be enrolled after UTI is treated and repeated UA and/or urine culture shows no further evidence of ongoing infection Evidence of injuries, bleeding, or evidence suggestive of dysplasia in the external vaginal area or vaginal canal
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Saranya Chumsri
    Organizational Affiliation
    Mayo Clinic
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy

    We'll reach out to this number within 24 hrs